FIELD: biotechnology, vaccines. SUBSTANCE: vaccine has protective pneumococcus antigens and preserving agent. Protein components of pneumococcus were used as protective antigens (molecular mass - 50, 60, 74, 80 and 94 kDa). Protective effect of vaccine is based on the use of T-dependent protein antigens. Vaccine is used for control and prophylaxis of pneumococcal infection. EFFECT: enhanced effectiveness as compared with polysaccharide antigens, prolonged protective effect for control of any known pneumococcus serotype.
| Title | Year | Author | Number |
|---|---|---|---|
| POLYVALENT PNEUMOCOCCAL VACCINES | 2019 |
|
RU2815390C2 |
| C-POLYSACCHARIDE-FREE CAPSULAR POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAE WITH A 2,5-ANHYDROMANOSE RESIDUE AT THE REDUCING END | 2023 |
|
RU2818894C1 |
| IMMUNOBIOLOGICAL AGENT BASED ON RECOMBINANT PROTEIN FOR PREVENTING PNEUMOCOCCAL INFECTION | 2024 |
|
RU2823752C1 |
| METHOD FOR FORMING IMMUNOLOGICAL MEMORY TO STREPTOCOCCUS PNEUMONIAE ANTIGENS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2014 |
|
RU2544168C1 |
| STREPTOCOCCUS PNEUMONIAE CAPSULE POLYSACCHARIDE AND ITS IMMUNOGENIC CONJUGATE | 2019 |
|
RU2803122C2 |
| MODIFIED PHEUMOLYSINE RECOMBINANT PLASMID, METHOD OF PRODUCING MODIFIED PHEUMOLYSINE AND VACCINE | 1989 |
|
RU2121481C1 |
| IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCUS VACCINES | 2016 |
|
RU2712622C2 |
| IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES | 2018 |
|
RU2762723C2 |
| INCREASE IN IMMUNOGENICITY OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES | 2018 |
|
RU2774891C2 |
| POLYVALENT COMPOSITION CONTAINING PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATES | 2013 |
|
RU2605834C2 |
